Oxana Beskrovnaya - Dec 4, 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Scientific Officer
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Stock symbol: DYN
Transactions as of: Dec 4, 2024
Transactions value $: $0
Form type: 4
Date filed: 12/6/2024, 04:05 PM
Previous filing: Nov 18, 2024
Next filing: Dec 11, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Award	$0	+39.1K	+28.43%	$0.00	177K	Dec 4, 2024	Direct	F1
transaction	DYN	Common Stock	Award	$0	+27.4K	+15.51%	$0.00	204K	Dec 4, 2024	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock option (right to buy)	Award	$0	+62.4K		$0.00	62.4K	Dec 4, 2024	Common Stock	62.4K	$29.44	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 39,100 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025.
F2	Consists of shares of Common Stock issuable under 27,400 RSUs. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in full on December 4, 2025.
F3	Includes 170,705 unvested RSUs.
F4	This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028.